2023-04-26 16:06:23 ET
- BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q1 Non-GAAP EPS of $0.60 beats by $0.20 .
- Revenue of $596.4M (+14.8% Y/Y) beats by $26.01M .
- Growth of VOXZOGO ® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 Guidance
- Full-year 2023 Top-line and Bottom-line Financial Guidance Reaffirmed; ROCTAVIAN™ Net Product Revenue Guidance Adjusted for Full-year 2023
- In Germany, Growing Pipeline of People with Severe Hemophilia A Getting Tested for ROCTAVIAN Treatment Eligibility; ROCTAVIAN U.S. Launch Preparations Underway Ahead of June 30 Prescription Drug User Fee Act Target Action Date.
- 2023 Outlook: Total Revenues $2,375-$2,500M, Gross Profit % 77.5 %-79%, Non-GAAP Diluted EPS $1.80-$2.05.
For further details see:
BioMarin Pharmaceutical Non-GAAP EPS of $0.60 beats by $0.20, revenue of $596.4M beats by $26.01M